Instructions on whether ibrutinib (ibrutinib) must be continued for a long time after taking it

Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor, mainly used to treat chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other hematological cancer diseases. Because its mechanism of action is to continuously inhibit the BTK signaling pathway, thereby blocking the proliferation and survival of tumor cells, ibrutinib is usually designed to be taken continuously for a long time in clinical practice to maintain efficacy and prevent disease recurrence.

Generally speaking, once ibrutinib is started, doctors usually recommend that patients continue taking it until intolerable side effects occur, the disease progresses, or the doctor adjusts the treatment plan based on the specific situation. Long-term continuous use can effectively inhibit tumor cells and prolong the progression-free survival and overall survival of patients. Both clinical trials and real-world studies have shown that disease can rebound rapidly after discontinuation of medication, so continued medication is seen as key to maintaining disease control.

However, long-term use of ibrutinib may also bring certain risks of side effects, such as bleeding, infection, arrhythmia, etc. Patients need to conduct regular monitoring and evaluation under the guidance of a doctor, and adjust the dose or take auxiliary measures according to the specific situation. After some patients achieve deep remission, physicians may consider dose reduction or observational discontinuation, but this requires careful evaluation and individualized risk.

In summary, the treatment model of ibrutinib emphasizes long-term continuous medication to maintain efficacy, which is the mainstream strategy in current clinical practice. Patients should strictly follow the doctor's instructions, insist on taking the medication and cooperate with regular examinations, and avoid stopping the medication or changing the dose on their own. If you encounter side effects or other questions, you should communicate with the attending doctor in time to ensure safe and effective treatment.

Reference materials:https://www.drugs.com